CD19-specific T cell Infusion in Patients with B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.

Trial Profile

CD19-specific T cell Infusion in Patients with B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Acute biphenotypic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
    • 10 Dec 2017 According to a Ziopharm Oncology media release, results from this trial were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 22 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top